2,4-dimethylthieno[2,3-d]pyrimidine | 111079-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 2,4-dimethylthieno[2,3-d]pyrimidine
• CAS: 111079-30-2
• 化学式: C₈H₈N₂S
• 分子量: 164.231
• InChiKey: XHRYEBHSKRMXFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,4-dimethylthieno[2,3-d]pyrimidine 、 溴 、 氯仿 以42%的产率得到
  参考文献：
  名称：

  KONNO, SHOETSU;WATANABE, RYO;YAMANAKA, HIROSHI, YAKUGAKU DZASSI, 109,(1989) N, S. 642-649

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氯-5-碘-2,6-二甲基嘧啶 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 硫化氢 、 sodium ethanolate 、 三乙胺 作用下， 以 乙醇 为溶剂， 反应 13.5h， 生成 2,4-dimethylthieno[2,3-d]pyrimidine
  参考文献：
  名称：

  Sakamoto, Takao; Kondo, Yoshinori; Watanabe, Ryo, Chemical and pharmaceutical bulletin, 1986, vol. 34, # 7, p. 2719 - 2724

  摘要：

  DOI：

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET UTILISATION DE CES COMPOSÉS
  申请人：NATIONAL HEALTH RES INST

  公开号：WO2018132326A1

  公开（公告）日：2018-07-19

  Heterocyclic compounds of Formula (I) shown herein. Also disclosed is a pharmaceutical composition containing one of the heterocyclic compounds. Further disclosed are methods of using one of the heterocyclic compounds for mobilizing hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation, and for treating tissue injury, cancer, inflammatory disease, and autoimmune disease.

  本文所示的式(I)的杂环化合物。还公开了含有其中一种杂环化合物的药物组合物。进一步公开了使用其中一种杂环化合物将造血干细胞和内皮祖细胞转移到外周循环，并用于治疗组织损伤、癌症、炎症性疾病和自身免疫疾病的方法。
• HETEROCYCLIC COMPOUNDS AND USE THEREOF
  申请人：National Health Research Institutes

  公开号：US20160083369A1

  公开（公告）日：2016-03-24

  Heterocyclic compounds of Formula (I) shown herein. Also disclosed are pharmaceutical compositions containing the heterocyclic compounds and methods of using the heterocyclic compounds to mobilize hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation. Further provided are methods for treating tissue injury, cancer, inflammatory disease, and autoimmune disease with the heterocyclic compounds.

  本文显示的式（I）的杂环化合物。还公开了含有这些杂环化合物的药物组合物以及使用这些杂环化合物将造血干细胞和内皮祖细胞转移到外周循环的方法。此外，还提供了使用这些杂环化合物治疗组织损伤、癌症、炎症性疾病和自身免疫疾病的方法。
• 5,6-Dimethylthieno[2,3-Di] Pyrimidine Derivatives, the Preparation Method Thereof and the Pharmaceutical Composition Comprising the Same for Anti-Virus
  申请人：Han Cheol Kyu

  公开号：US20080234482A1

  公开（公告）日：2008-09-25

  Disclosed herein are 5,β-dimethylthieno[2,3-d]pyrimidine derivatives useful as antiviral agents. More particularly, disclosed are 5,β-dimethylthieno[2,3-djpyrimidine derivatives represented by Formula 1, having an excellent inhibitory effect on the proliferation of hepatitis C virus (HCV), pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the prevention and treatment of hepatitis C virus (HCV), containing, as active ingredients, these compounds. The 5,6-dimethylthieno[2,3-d]pyrimidine derivatives represented by Formula 1 have an excellent effect of inhibiting the proliferation of hepatitis C virus and also have low toxicity. Thus, these compounds are available as agents for the prevention and treatment of hepatitis C.

  本文披露了一种作为抗病毒剂有用的5,β-二甲基噻吩[2,3-d]嘧啶衍生物。更具体地，披露了由式1表示的5,β-二甲基噻吩[2,3-d]嘧啶衍生物，其对丙型肝炎病毒（HCV）增殖具有优异的抑制作用，其药学上可接受的盐，其制备方法以及包含这些化合物作为活性成分的用于预防和治疗丙型肝炎病毒（HCV）的制药组合物。由式1表示的5,6-二甲基噻吩[2,3-d]嘧啶衍生物具有优异的抑制丙型肝炎病毒增殖的效果，同时毒性较低。因此，这些化合物可用作预防和治疗丙型肝炎的药物。
• INHIBITORS OF THE USP1/UAF1 DEUBIQUITINASE COMPLEX AND USES THEREOF
  申请人：THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN

  公开号：US20150344443A1

  公开（公告）日：2015-12-03

  Disclosed are inhibitors of the USP1/UAF1 deubiquitinase complex, for example. of formula (I), wherein R 1 , R 2 , and Q are as defined herein, which are useful in treating diseases such as cancer, and improving the efficacy of DNA damaging agents in cancer treatment. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a heterodimeric deubiquitinase complex in a cell, and a method of enhancing the chemotherapeutic treatment of cancer in a mammal undergoing treatment with an anti cancer agent. Further disclosed is a method of preparing compounds of the invention.

  本发明涉及抑制USP1/UAF1去泛素化酶复合物的抑制剂，例如式（I）中定义的R1、R2和Q，其对于治疗癌症和提高DNA损伤剂在癌症治疗中的疗效非常有用。本发明还涉及一种包含药学适用载体和本发明中至少一种化合物的组合物，一种在细胞中抑制异源二聚体去泛素化酶复合物的方法，以及一种增强正在接受抗癌药物治疗的哺乳动物的化疗治疗的方法。本发明还涉及一种制备本发明化合物的方法。
• Aromatic Compound
  申请人：Furukubo Shigeru

  公开号：US20090182142A1

  公开（公告）日：2009-07-16

  An aromatic compound represented by the following formula or a pharmaceutically acceptable salt thereof: , wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., G 1 , G 2 , G 3 , G 4 and G 5 are CH or N, X is —NH—, —O—, —CH 2 —, etc., Y is —CH 2 —, —CO—, —SO 2 —, etc., Z is a single bond, —CO—, —SO 2 —, —NH—, —O—, —S—, —CONH—, —SO 2 NH—, etc., R 2 is hydrogen, alkyl, alkoxy, halogen, etc., and R 3 is carbocyclic group, heterocyclic group, alkyl, etc., is useful as a controlling agent of the function of CCR4 useful for the treatment or therapy for bronchial asthma, atopic dermatitis, etc.

  下列的芳香族化合物或其药学上可接受的盐，其化学式如下：其中环A为杂环，环B为碳环、杂环等，G1、G2、G3、G4和G5为CH或N，X为—NH—、—O—、—CH2—等，Y为—CH2—、—CO—、—SO2—等，Z为单键、—CO—、—SO2—、—NH—、—O—、—S—、—CONH—、—SO2NH—等，R2为氢、烷基、烷氧基、卤素等，而R3为碳环基、杂环基、烷基等。该化合物对于控制CCR4功能的作用剂对于治疗或治疗支气管哮喘、特应性皮炎等疾病是有用的。